Bliss GVS Pharma Limited has informed the Exchange regarding Board meeting held on September 30, 2025.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma's board, at its meeting on September 30, 2025, approved the appointment of Mr. Narsimha Shibroor Kamath as Chief Executive Officer with immediate effect. Mr. Kamath is the founder and Promoter of the company, who originally acquired Bliss Chemicals & Pharmaceuticals and built the business into one exporting to over 60 countries. The appointment is for an unspecified term, with the board meeting running from 4:15 PM to 5:00 PM. His profile and relationship disclosures show he is the father-in-law of the Managing Director (Mr. Gagan Sharma) and father of two Whole-Time Directors (Dr. Vibha Sharma and Mrs. Shruti Rao).
Leadership is now fully in promoter-family hands, with the founder as CEO, his son-in-law as MD, and his two daughters as Whole-Time Directors. This sharpens strategic direction under the original promoter but concentrates decision-making and raises corporate governance concerns for minority shareholders.